The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Black Diamond Therapeutics Inc (NASDAQ: BDTX) was $5.44 for the day, down -5.23% from the previous closing price of $5.74. In other words, the price has decreased by -$5.23 from its previous closing price. On the day, 2.53 million shares were traded. BDTX stock price reached its highest trading level at $5.855 during the session, while it also had its lowest trading level at $5.4.
Ratios:
Our analysis of BDTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.05 and its Current Ratio is at 7.05. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.20.
On June 30, 2023, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $10.
H.C. Wainwright Upgraded its Neutral to Buy on June 28, 2023, while the target price for the stock was maintained at $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 17 ’23 when BIOTECH GROWTH N V bought 400,000 shares for $2.34 per share. The transaction valued at 934,080 led to the insider holds 8,517,839 shares of the business.
Behbahani Ali bought 1,000,000 shares of BDTX for $5,000,000 on Jul 05 ’23. The Director now owns 4,448,757 shares after completing the transaction at $5.00 per share. On Jul 05 ’23, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the Director of the company, bought 935,850 shares for $5.00 each. As a result, the insider paid 4,679,250 and bolstered with 3,213,828 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BDTX now has a Market Capitalization of 306096832 and an Enterprise Value of 191912288.
Stock Price History:
The Beta on a monthly basis for BDTX is 2.55, which has changed by 2.3580246 over the last 52 weeks, in comparison to a change of 0.2644323 over the same period for the S&P500. Over the past 52 weeks, BDTX has reached a high of $7.66, while it has fallen to a 52-week low of $1.57. The 50-Day Moving Average of the stock is 2.64%, while the 200-Day Moving Average is calculated to be 50.60%.
Shares Statistics:
BDTX traded an average of 622.90K shares per day over the past three months and 907280 shares per day over the past ten days. A total of 51.65M shares are outstanding, with a floating share count of 46.33M. Insiders hold about 17.63% of the company’s shares, while institutions hold 57.02% stake in the company. Shares short for BDTX as of 1714435200 were 1996436 with a Short Ratio of 3.21, compared to 1711584000 on 2044244. Therefore, it implies a Short% of Shares Outstanding of 1996436 and a Short% of Float of 6.75.
Earnings Estimates
Black Diamond Therapeutics Inc (BDTX) is currently under the scrutiny of 6.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.45, while EPS last year was -$0.52. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.29 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.29 and -$1.84 for the fiscal current year, implying an average EPS of -$1.51. EPS for the following year is -$1.6, with 5.0 analysts recommending between -$1.27 and -$2.16.
